Abstract Myelodysplastic syndrome (MDS) is frequently associated with clonal cytogenetic abnormalities which are major predictors of the disease outcome. t(3;8)(q26;q24) was reported as a rare recurrent cytogenetic abnormality in MDS/acute myeloid leukemia (AML) with poor prognosis.
Introduction
Myelodysplastic syndromes (MDSs) are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia, and impaired hematopoiesis [1, 2] . Primary MDS occurs principally in elderly adults with a median age of 70 years old.
Clonal cytogenetic abnormalities are observed in~50 % of MDS cases. The most common abnormalities are complex karyotype, del(5q), trisomy 8, and del(20q) [2] [3] [4] . Other recurring abnormalities include abnormalities in chromosome 7 and balanced translocations involving chromosomes 11, 16, 3, and 21, such as t(11;16)(q23;p13.3), t(3;21)(q26.2;p22.1), t(1;3)(p36.3;q21.2), t(2;11)(p21;q23), t(6;9)(p23;q34), and inv(3)(q21q26.2) [2] .
Cytogenetic and molecular studies have a major prognostic significance in MDS and are predictive of disease progression and survival. They have been incorporated in the IPSS score which is commonly used to estimate survival of patients with MDS [2] . The prognostic significance of less common chromosomal abnormalities is not well determined due to the paucity of reported cases.
Recently, t(3;8)(q26;q24) was reported as a rare recurrent cytogenetic abnormality in MDS/acute myeloid leukemia (AML) associated with poor prognosis [5] . Here, we present a case of an 84-year-old patient with MDS/AML with t(3;8)(q26;q24), who manifested an aggressive disease course.
Materials and methods
Wright-Giemsa-stained peripheral blood and bone marrow aspirate smears and hematoxylin and eosin (H&E)-stained core biopsy specimens were reviewed. Immunohistochemical stains were performed as per manufacturer's instructions on the Leica Bond III autostainer (Leica Microsystems, Newcastle, UK), using the Bond Polymer Refine Detection System (DS9800, Newcastle, UK) on 4-μm-thick formalin-fixed, paraffin-embedded All antibodies were purchased from BD Biosciences (San Jose, CA, USA), and the analyses were performed using the BD FACSCanto II (BD Biosciences). For each antibody, negative staining levels were set by comparison with an isotype-matched control.
Conventional cytogenetic analysis was performed on metaphase cells from BM aspirate cultured for 24 h without mitogens using standard techniques. Giemsa-banded metaphases were analyzed, and the results were reported using the International System for Human Cytogenetic Nomenclature, 2005.
Results/case report

Initial presentation
An 84-year-old Caucasian male presented in May 2009 with macrocytic anemia, thrombocytopenia, and fatigue for 7 months. [12] /46,XY [5] .
Peripheral smear showed anisocytosis, dysplastic neutrophils with pseudo-Pelger-Huet anomaly, circulating megakaryocytic remnants, and hypogranular platelets.
Bone marrow aspirate demonstrated normocellular marrow (30-40 %) with trilineage maturation, hematopoiesis with granulocytic left shift, dysplastic mononuclear megakaryocytes, and increased myeloid blasts (7 %) (Fig. 1a) .
Bone marrow biopsy showed a normocellular marrow with trilineage maturation but decreased granulocyte-toerythroid ratio, left-shifted granulopoiesis, and increased dysplastic mononuclear megakaryocytes (Fig. 2) . Diagnosis of myelodysplasia-refractory anemia with excess blasts (RAEB1)-was made.
Transformation to acute leukemia
In October 2009, the patient had increased fatigue, and his transfusion requirements increased to 6 units of red blood cells per month, At that time, complete blood count showed WBC 6.7×10 9 /l, Hgb 8.7 g/dL, MCV 92.2 fL, and platelet count 121×10 9 /l. Immunophenotyping of peripheral blood by flow cytometry identified abnormal CD45 − /CD42b + /CD61 + megakaryocytic precursor population (50 % of the sample) that was negative for CD34, CD45, CD117, and all other myeloid and lymphoid antigens tested (CD3, CD13, CD14, CD19, and CD56) (Fig. 3a) . Cytogenetic evaluation showed an abnormal clone with an apparent translocation between the long arm of chromosome 3 and the long arm of chromosome 8 and an additional copy of chromosome 14. Of note, a clone with +14 and added material on 8q was seen in the first bone marrow preparation, but structural changes on chromosome 3 were not seen (Fig. 3b) .
Significant numbers of small megakaryocytic nuclear fragments were detected (Fig. 1b) , and red cell anisopoikilocytosis with increased ovalocytes, acanthocytes, and schistocytes was seen in the peripheral smear.
Bone marrow aspirate and biopsy were repeated, giving suspicion for disease progression. The aspirate was a particulate and hemodiluted. The biopsy showed increased marrow cellularity ranging from 40 to 90 % with fibrosis, decreased erythropoiesis, left-shifted granulopoiesis with atypically localized immature precursors, and increased small dysplastic mononuclear megakaryocytes.
The immunostaining revealed that a significant portion of the immature precursors were myeloperoxidase-positive (Fig. 4) , and a subset also expressed CD117. There was a minimal expression of CD34. CD61 stain confirmed the increased numbers of dysplastic mononuclear megakaryocytes. CR case report (single patient is reported), SLF/TLF(m) status at the last follow-up/time of the last follow-up in months, A alive, D deceased, NI no information available, AML, NOS acute myeloid leukemia, not otherwise specified, t-AML therapy-related AML, MCL mantle cell lymphoma, AMML acute myelomonocytic leukemia, HL Hodgkin lymphoma, CML chronic myelogenous leukemia, CMML chronic myelomonocytic leukemia, M male, F female
Final pathologic diagnosis of MDS with fibrosis and progression to acute myeloid leukemia was rendered (AML with myelodysplasia-related changes).
Following diagnosis, patient was started on lenalidomide and prednisone. Patient's hemoglobin increased to 8.3-9.0 g/dL, and platelet count returned to normal. This was accompanied by the disappearance of circulating blasts and megakaryocytic fragments and a 25 % decrease in transfusion requirement. In December 2009, patient developed fevers and myalgias and was admitted to the hospital with pancytopenia and sepsis. He elected to pursue comfort measures and died 7 months after the initial diagnosis of MDS.
Discussion
The reported case is of an 84-year-old patient who presented initially with macrocytic anemia, mild thrombocytopenia, and fatigue and was diagnosed with MDS/RAEB1. The patient quickly became transfusion-dependent, manifested progression to acute leukemia with extensive myelofibrosis and dysmegakaryopoiesis, and expired 7 months after initial diagnosis of MDS. Cytogenetic evaluation of bone marrow showed 47,XY,t(3:8)(q26;q24),+14 [11] which was first detected at the time of the transformation.
Recurrent translocation or inversion between regions of 3q21 and 3q26, most commonly inv(3)(q21q26) and t(3;3)(q21;26), gives rise to the so-called "3q21q26 syndrome." Rearrangement of 3q26 has been described in 5 % of MDS cases and also noted in AML and chronic myeloid leukemia in blast crisis [6] . The distinctive clinical features are normal or elevated platelet count at the initial presentation, hyperplasia and dysplasia of megakaryocytes, and aggressive course with poor response to therapy.
Association of MDS and AML with cytogenetic aberration t(3;8)(q26;q24) has been described in a total of 14 patients [3, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] (Table 1) . Poor outcome was a characteristic of this group. Two patients also demonstrated marked thrombocytosis.
Low normal platelet count and dysmegakaryopoiesis with circulating megakaryoblasts were distinguishing features.
The 3q26.2 chromosome band contains ectopic viral integration gene (EVI1) [19] . EVI1 is a proto-oncogene that is involved in the development of myeloid-type leukemia with poor prognosis [5, 20, 21] . The gene encodes a nuclear DNA-binding zinc finger protein [19] . It is aberrantly expressed in AML and MDS, which exhibit rearrangements of 3q26. In normal tissues, EVI1 is found in a longer variant, MDS-EVI1, and encodes a protein that functions as a negative regulator of tumorigenesis. Breakpoints of various translocations are heterogeneous and are located both upstream and downstream of the EVI1 coding region, leading to inappropriate EVI1 activation under the putative promoters located on 3q21. Ribophorin I and GR6 were implicated as fusion partners of EVI1. In case of t(3;3), ribophorin I is translocated upstream, and in case of inv(3), it is translocated downstream of EVI1 [22] .
Lennon and colleagues demonstrated that in AML with t(3:8)(q26;q24), the breakpoints are located at the EVI1/MDS1 locus on chromosome 3 and are distal to plasmacytoma variant translocation 1 (PVT1) on chromosome 8 [5] . Overexpression of EVI1 protein and PVT1 amplification ensue. PVT1 is an oncogene homolog that activates C-MYC which in turn enhances cell proliferation [23] . t(3:8)(q26;q24) typically involves aberrant overexpression of EVI1 regardless of the heterogeneous breakpoints and various fusion partners [5] .
The translocation t(3:8)(q26;q24) was seen in association with monosomy of chromosome 7 in 6 of 14 reported patients. The loss of chromosome 7 is a frequent abnormality in MDS, AML, and "3q26 syndrome" and is part of the so-called "monosomal karyotype" indicating poor prognosis. Five of 16 patients had t(3:8)(q26;q24) as a sole genetic abnormality. Our patient showed a 47,XY karyotype with an additional copy of chromosome 14. One of five patients in Lin's study who presented with de novo AML and fatal outcome in 7 months also had a 47,XY karyotype with additional chromosome 13 [6] .
The molecular (EVI1 expression) and clinicomorphological (dysmegakaryopoiesis with normal/high platelets and aggressive clinical course) features of cases with t(3:8)(q26;q24) resemble 3q21q26 syndrome which has poor prognosis. Our prior reports show that t(3:8)(q26;q24) in MDS/AML is also associated with unfavorable prognosis. In our case, the cytogenetic abnormality was first demonstrated at the time of transformation to AML. Additional cases may help to delineate t(3:8)(q26;q24) as a marker of aggressive disease with poor outcome in MDS/AML.
